Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dotinurad in Adult Participants With Gout Who Are Intolerant to Xanthine Oxidase Inhibitors or Failed Uricase Treatment
NCT07535034Phase 2Recruiting
- Sponsor
- Crystalys Therapeutics
- Start
- May 2026
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dotinurad in gout, sponsored by Crystalys Therapeutics. Started May 2026; status: recruiting.
02
Drugs
dotinurad
03
Conditions
gout
Beyond the preview
Go deeper on NCT07535034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07535034.